Compared to controls, cyst reduction reached 39% (pVAX-GRA28), 34% (pVAX-GRA83), 54% (dual-antigen), and 81% (pVAX-IL-28B-adjuvanted triple combination). This evidence concerns the gene IFNL3 and cyst.